Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meloxicam
Drug ID BADD_D01374
Description Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.[A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Indications and Usage For symptomatic treatment of arthritis and osteoarthritis.
Marketing Status Prescription; Discontinued
ATC Code M01AC06
DrugBank ID DB00814
KEGG ID D00969
MeSH ID D000077239
PubChem ID 54677470
TTD Drug ID D0G7FJ
NDC Product Code 61919-469; 38779-2746; 67296-1317; 29300-125; 68788-7904; 63629-2020; 71610-583; 0615-8124; 70518-1828; 65841-051; 43063-396; 43063-401; 72865-138; 69344-205; 80425-0043; 61919-434; 71610-580; 68071-4987; 71610-544; 42708-093; 65862-097; 70518-3023; 43063-395; 50090-5339; 51552-1377; 50436-1125; 17373-1157; 56125-750; 70954-077; 70859-007; 69344-206; 17373-1158; 72969-045; 60760-419; 60760-448; 43353-979; 80425-0045; 51869-0008; 76282-153; 65841-050; 70934-010; 60592-994; 72865-137; 59349-0003; 53002-1537; 50090-5861; 0615-8040; 53747-006; 68071-1919; 53069-0790; 50090-0986; 67296-1817; 50436-1124; 68071-3030; 71335-0406; 51407-610; 45865-360; 68382-050; 35356-808; 69097-159; 67296-0583; 54458-964; 50090-5340; 68180-502; 51407-611; 61442-126; 50090-0985; 61442-127; 71205-923; 43353-127; 68382-051; 80425-0041; 71518-001; 67296-0823; 68225-112; 16571-776; 50268-526; 51869-0007; 52119-003; 71610-542; 76282-152; 55289-618; 67296-1250; 49452-4402; 71335-1888; 68981-032; 60760-404; 70954-076; 42708-007; 68462-141; 68180-501; 65862-098; 70518-0039; 53002-2535; 71205-924; 54458-965; 80425-0042; 53104-7574; 68071-1993; 50090-4896; 70518-0200; 43353-038; 0395-8154; 68071-1994; 68071-2184; 60687-199; 53002-1535; 80425-0083; 65862-223; 68180-189; 68788-1701; 0597-0029; 70518-2631; 0597-0030; 64380-715; 68788-9418; 50268-525; 71610-380; 68462-140; 63629-3328; 29300-124; 69097-158; 76420-043; 51655-731; 63629-2019; 58118-1158; 68788-7726; 53002-2537; 71335-1956; 63629-7966; 64380-716; 71335-1618; 65841-004; 63187-082; 62938-0026; 63187-083; 71610-516; 68180-188; 16571-777; 70518-1299; 51927-0032; 70518-0031; 49999-869; 80425-0044; 76420-039; 51655-577; 63629-3248; 55289-272; 70518-0171; 22365-116; 58624-0430
Synonyms Meloxicam | Miloxicam | Parocin | Mobic | Mobicox | Mobec | Masflex | Movicox | Reumoxicam | Uticox | Movalis
Chemical Information
Molecular Formula C14H13N3O4S2
CAS Registry Number 71125-38-7
SMILES CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gait disturbance17.02.05.016; 08.01.02.0020.000147%
Gamma-glutamyltransferase increased13.03.01.011--
Gastric haemorrhage24.07.02.007; 07.12.01.0010.000953%
Gastric perforation12.02.03.007; 07.04.03.0010.000110%
Gastric ulcer07.04.03.0020.000550%
Gastric ulcer haemorrhage24.07.02.003; 07.04.03.0050.000110%Not Available
Gastric ulcer perforation07.04.03.006--Not Available
Gastritis07.08.02.0010.000220%
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.001210%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.000183%Not Available
Haematochezia07.12.02.003; 24.07.02.0120.000330%Not Available
Haematocrit decreased13.01.05.0010.000110%Not Available
Haematuria20.02.01.006; 24.07.01.047--
Haemoglobin decreased13.01.05.0030.000550%Not Available
Headache17.14.01.001--
Heart rate decreased13.14.04.0010.000110%Not Available
Heart rate increased13.14.04.0020.000110%Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.000183%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000073%Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis cholestatic09.01.01.0020.000330%Not Available
Hepatocellular injury09.01.07.0080.000110%Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkalaemia14.05.03.0010.000147%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages